TY - JOUR
T1 - Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies
AU - Selleri, Marina
AU - Orchi, Nicoletta
AU - Zaniratti, Maria Stefania
AU - Bellagamba, Rita
AU - Corpolongo, Angela
AU - Angeletti, Claudio
AU - Ippolito, Giuseppe
AU - Capobianchi, Maria Rosaria
AU - Girardi, Enrico
PY - 2007/10
Y1 - 2007/10
N2 - OBJECTIVE: To evaluate if the administration of highly active antiretroviral therapy (HAART) during primary HIV infection (PHI) may affect the antibody avidity evolution. METHODS: In 13 subjects with symptomatic PHI, of whom 8 initiated HAART at diagnosis, the Avidity Index (AI) and Western blot evolution patterns were analyzed on serial serum/plasma samples for 1 year. In 4 patients, who subsequently interrupted HAART, additional specimens were analyzed. RESULTS: At diagnosis, the range of HIV viremia was 0.003 to 38 × 10 copies/mL. In untreated patients, viremia reached the set point in 4 to 6 months, whereas in treated patients, early suppression of viremia was observed, remaining undetectable during therapy. At diagnosis, the median AI was low in untreated (0.42, range: 0.33 to 0.43) and treated (0.44, range: 0.40 to 0.72) patients. At 3, 6, and 12 months, the AI progressively increased in untreated patients, whereas it remained
AB - OBJECTIVE: To evaluate if the administration of highly active antiretroviral therapy (HAART) during primary HIV infection (PHI) may affect the antibody avidity evolution. METHODS: In 13 subjects with symptomatic PHI, of whom 8 initiated HAART at diagnosis, the Avidity Index (AI) and Western blot evolution patterns were analyzed on serial serum/plasma samples for 1 year. In 4 patients, who subsequently interrupted HAART, additional specimens were analyzed. RESULTS: At diagnosis, the range of HIV viremia was 0.003 to 38 × 10 copies/mL. In untreated patients, viremia reached the set point in 4 to 6 months, whereas in treated patients, early suppression of viremia was observed, remaining undetectable during therapy. At diagnosis, the median AI was low in untreated (0.42, range: 0.33 to 0.43) and treated (0.44, range: 0.40 to 0.72) patients. At 3, 6, and 12 months, the AI progressively increased in untreated patients, whereas it remained
KW - Antibody avidity
KW - Antigen-antibody reactions
KW - Highly active antiretroviral therapy
KW - Primary HIV-1 infection
KW - Viral replication
UR - http://www.scopus.com/inward/record.url?scp=34748856217&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34748856217&partnerID=8YFLogxK
U2 - 10.1097/QAI.0b013e318120039b
DO - 10.1097/QAI.0b013e318120039b
M3 - Article
C2 - 17589369
AN - SCOPUS:34748856217
VL - 46
SP - 145
EP - 150
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
SN - 1525-4135
IS - 2
ER -